Please login to the form below

Not currently logged in
Email:
Password:

Kazano

This page shows the latest Kazano news and features for those working in and with pharma, biotech and healthcare.

FDA investigates pancreas risk of diabetes drugs

FDA investigates pancreas risk of diabetes drugs

Newer DPP-4 inhibitors Tradjenta (linagliptin) from Boehringer Ingelheim and Takeda's alogliptin-based medicines (Nesina, Kazano and Oseni) are also affected.

Latest news

  • Takeda gets FDA approval for alogliptin franchise in diabetes Takeda gets FDA approval for alogliptin franchise in diabetes

    Takeda gets FDA approval for alogliptin franchise in diabetes. Comprises Nesina, Oseni and Kazano. ... The US agency approved Takeda's DPP-4 inhibitor Nesina (alogliptin) - along with two fixed-dose combination products Oseni (alogliptin and pioglitazone)

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
COUCH.

WE ARE COUCH – a full service medical communications agency. We are a trusted partner; always striving to help make...

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Infographics